{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:01:16Z","timestamp":1781640076647,"version":"3.54.5"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004442","name":"National Science Centre","doi-asserted-by":"crossref","award":["2020\/37\/B\/NZ4\/02533"],"award-info":[{"award-number":["2020\/37\/B\/NZ4\/02533"]}],"id":[{"id":"10.13039\/501100004442","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Liver cancer often arises in the setting of chronic liver disease and remains a major global health challenge with limited effective treatments. Isoprenylcysteine Carboxyl Methyltransferase (ICMT) is an enzyme that catalyzes the methylation of prenylated proteins containing a CAAX motif, such as RAS, a modification thought to be essential for their function. Given its role in oncogenic signaling, ICMT has emerged as a potential therapeutic target in cancer. Notably, ICMT is overexpressed in human hepatocellular carcinoma (HCC), and previous studies have shown that\n                    <jats:italic>Icmt<\/jats:italic>\n                    deletion impairs\n                    <jats:italic>Braf<\/jats:italic>\n                    <jats:sup>V600E<\/jats:sup>\n                    -driven transformation in murine fibroblasts. In this study, we investigated the role of ICMT in liver cancer using a genetically engineered mouse model with hepatocyte-specific expression of\n                    <jats:italic>Braf<\/jats:italic>\n                    <jats:sup>V600E<\/jats:sup>\n                    , combined with deletion of\n                    <jats:italic>Trp53<\/jats:italic>\n                    and\n                    <jats:italic>Icmt<\/jats:italic>\n                    . We assessed the impact of\n                    <jats:italic>Icmt<\/jats:italic>\n                    loss on liver physiology, tumorigenesis, and global transcriptomic and proteomic landscapes. Expression of\n                    <jats:italic>Braf<\/jats:italic>\n                    <jats:sup>V600E<\/jats:sup>\n                    led to progressive body weight loss, reduced survival, hepatomegaly, vascular congestion, liver fibrosis, and tumor development. These phenotypic changes were associated with widespread alterations in gene and protein expression, particularly affecting pathways related to cell differentiation, coagulation, and metabolism. Strikingly, liver-specific\n                    <jats:italic>Icmt<\/jats:italic>\n                    deletion ameliorated several pathological features, including weight loss, early mortality, fibrosis, and vascular abnormalities. It also partially normalized the transcriptomic and proteomic profiles. However\n                    <jats:italic>, Icmt<\/jats:italic>\n                    deletion did not prevent hepatomegaly or tumor formation. In conclusion, while ICMT deletion mitigates several deleterious effects of\n                    <jats:italic>Braf<\/jats:italic>\n                    <jats:sup>V600E<\/jats:sup>\n                    -driven liver pathology, it does not block tumorigenesis. These findings suggest that ICMT is not a suitable therapeutic target for liver cancer prevention or treatment, but may have potential as a target to alleviate liver disease-associated symptoms.\n                  <\/jats:p>","DOI":"10.1186\/s12964-026-02775-6","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T01:04:57Z","timestamp":1773191097000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["ICMT deficiency ameliorates weight loss and mortality, but not tumor formation in a mouse model of liver cancer"],"prefix":"10.1186","volume":"24","author":[{"given":"Piotr","family":"Czarnota","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Gromowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Golda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danuta","family":"Bryzek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Slawomir","family":"Lasota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Koziel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mateusz","family":"Wilamowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaroslaw","family":"Cisowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"key":"2775_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75:10\u201345. https:\/\/doi.org\/10.3322\/caac.21871.","journal-title":"CA Cancer J Clin"},{"key":"2775_CR2","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","volume":"77","author":"H Rumgay","year":"2022","unstructured":"Rumgay H, Arnold M, Ferlay J, Lesi O, Cabasag CJ, Vignat J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022;77:1598\u2013606. https:\/\/doi.org\/10.1016\/j.jhep.2022.08.021.","journal-title":"J Hepatol"},{"key":"2775_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7:6. https:\/\/doi.org\/10.1038\/s41572-020-00240-3.","journal-title":"Nat Rev Dis Primers"},{"key":"2775_CR4","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2025.2455539","volume":"57","author":"J Wang","year":"2025","unstructured":"Wang J, Qiu K, Zhou S, Gan Y, Jiang K, Wang D, et al. Risk factors for hepatocellular carcinoma: an umbrella review of systematic review and meta-analysis. Ann Med. 2025;57:2455539. https:\/\/doi.org\/10.1080\/07853890.2025.2455539.","journal-title":"Ann Med"},{"key":"2775_CR5","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/hep.29466","volume":"67","author":"C Estes","year":"2018","unstructured":"Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67:123\u201333. https:\/\/doi.org\/10.1002\/hep.29466.","journal-title":"Hepatology"},{"key":"2775_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.601710","author":"D Suresh","year":"2020","unstructured":"Suresh D, Srinivas AN, Kumar DP. Etiology of hepatocellular carcinoma: special focus on fatty liver disease. Front Oncol. 2020. https:\/\/doi.org\/10.3389\/fonc.2020.601710.","journal-title":"Front Oncol"},{"key":"2775_CR7","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1016\/j.jhep.2011.10.027","volume":"56","author":"G Baffy","year":"2012","unstructured":"Baffy G, Brunt EM, Caldwell SH. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol. 2012;56:1384\u201391. https:\/\/doi.org\/10.1016\/j.jhep.2011.10.027.","journal-title":"J Hepatol"},{"key":"2775_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-00264-x","volume":"5","author":"A Huang","year":"2020","unstructured":"Huang A, Yang X-R, Chung W-Y, Dennison AR, Zhou J. Targeted therapy for hepatocellular carcinoma. Signal Transduct Target Ther. 2020;5:146. https:\/\/doi.org\/10.1038\/s41392-020-00264-x.","journal-title":"Signal Transduct Target Ther"},{"key":"2775_CR9","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.jhep.2009.03.028","volume":"51","author":"P Newell","year":"2009","unstructured":"Newell P, Toffanin S, Villanueva A, Chiang DY, Minguez B, Cabellos L, et al. Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol. 2009;51:725\u201333. https:\/\/doi.org\/10.1016\/j.jhep.2009.03.028.","journal-title":"J Hepatol"},{"key":"2775_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13123026","volume":"13","author":"H Moon","year":"2021","unstructured":"Moon H, Ro SW. MAPK\/ERK signaling pathway in hepatocellular carcinoma. Cancers (Basel). 2021;13:3026. https:\/\/doi.org\/10.3390\/cancers13123026.","journal-title":"Cancers (Basel)"},{"key":"2775_CR11","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/j.jhep.2018.07.004","volume":"69","author":"C Wang","year":"2018","unstructured":"Wang C, Jin H, Gao D, Lieftink C, Evers B, Jin G, et al. Phospho-ERK is a biomarker of response to a synthetic lethal drug combination of sorafenib and MEK inhibition in liver cancer. J Hepatol. 2018;69:1057\u201365. https:\/\/doi.org\/10.1016\/j.jhep.2018.07.004.","journal-title":"J Hepatol"},{"key":"2775_CR12","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1006\/bbrc.1997.6840","volume":"236","author":"CM Schmidt","year":"1997","unstructured":"Schmidt CM, McKillop IH, Cahill PA, Sitzmann JV. Increased MAPK Expression and Activity in Primary Human Hepatocellular Carcinoma. Biochem Biophys Res Commun. 1997;236:54\u20138. https:\/\/doi.org\/10.1006\/bbrc.1997.6840.","journal-title":"Biochem Biophys Res Commun"},{"key":"2775_CR13","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jhep.2007.08.018","volume":"48","author":"KJ Schmitz","year":"2008","unstructured":"Schmitz KJ, Wohlschlaeger J, Lang H, Sotiropoulos GC, Malago M, Steveling K, et al. Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection. J Hepatol. 2008;48:83\u201390. https:\/\/doi.org\/10.1016\/j.jhep.2007.08.018.","journal-title":"J Hepatol"},{"key":"2775_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-7-41","author":"Z Zhang","year":"2009","unstructured":"Zhang Z, Zhou X, Shen H, Wang D, Wang Y. Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study. 2009. https:\/\/doi.org\/10.1186\/1741-7015-7-41.","journal-title":"Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study"},{"key":"2775_CR15","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nrm.2015.11","volume":"17","author":"M Wang","year":"2016","unstructured":"Wang M, Casey PJ. Protein prenylation: unique fats make their mark on biology. Nat Rev Mol Cell Biol. 2016;17:110\u201322. https:\/\/doi.org\/10.1038\/nrm.2015.11.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2775_CR16","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1182\/blood-2007-06-094060","volume":"112","author":"AM Wahlstrom","year":"2008","unstructured":"Wahlstrom AM, Cutts BA, Liu M, Lindskog A, Karlsson C, Sjogren A-KM, et al. Inactivating Icmt ameliorates K-RAS\u2013induced myeloproliferative disease. Blood. 2008;112:1357\u201365. https:\/\/doi.org\/10.1182\/blood-2007-06-094060.","journal-title":"Blood"},{"key":"2775_CR17","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1172\/JCI18829","volume":"113","author":"MO Bergo","year":"2004","unstructured":"Bergo MO, Gavino BJ, Hong C, Beigneux AP, McMahon M, Casey PJ, et al. Inactivation of Icmt inhibits transformation by oncogenic K-Ras and B-Raf. J Clin Investig. 2004;113:539\u201350. https:\/\/doi.org\/10.1172\/JCI18829.","journal-title":"J Clin Investig"},{"key":"2775_CR18","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.bbrc.2019.08.094","volume":"518","author":"J Xu","year":"2019","unstructured":"Xu J, Zhu Y, Wang F, Zhou Y, Xia G, Xu W. ICMT contributes to hepatocellular carcinoma growth, survival, migration and chemoresistance via multiple oncogenic pathways. Biochem Biophys Res Commun. 2019;518:584\u20139. https:\/\/doi.org\/10.1016\/j.bbrc.2019.08.094.","journal-title":"Biochem Biophys Res Commun"},{"key":"2775_CR19","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1074\/jbc.274.1.305","volume":"274","author":"C Postic","year":"1999","unstructured":"Postic C, Shiota M, Niswender KD, Jetton TL, Chen Y, Moates JM, et al. Dual Roles for Glucokinase in Glucose Homeostasis as Determined by Liver and Pancreatic \u03b2 Cell-specific Gene Knock-outs Using Cre Recombinase. J Biol Chem. 1999;274:305\u201315. https:\/\/doi.org\/10.1074\/jbc.274.1.305.","journal-title":"J Biol Chem"},{"key":"2775_CR20","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1101\/gad.1516407","volume":"21","author":"D Dankort","year":"2007","unstructured":"Dankort D, Filenova E, Collado M, Serrano M, Jones K, McMahon M. A new mouse model to explore the initiation, progression, and therapy of BRAF V600E -induced lung tumors. Genes Dev. 2007;21:379\u201384. https:\/\/doi.org\/10.1101\/gad.1516407.","journal-title":"Genes Dev"},{"key":"2775_CR21","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/ng747","volume":"29","author":"J Jonkers","year":"2001","unstructured":"Jonkers J, Meuwissen R, van der Gulden H, Peterse H, van der Valk M, Berns A. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet. 2001;29:418\u201325. https:\/\/doi.org\/10.1038\/ng747.","journal-title":"Nat Genet"},{"key":"2775_CR22","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nmeth.3317","volume":"12","author":"D Kim","year":"2015","unstructured":"Kim D, Langmead B, Salzberg SL. HISAT: a fast spliced aligner with low memory requirements. Nat Methods. 2015;12:357\u201360. https:\/\/doi.org\/10.1038\/nmeth.3317.","journal-title":"Nat Methods"},{"key":"2775_CR23","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","volume":"30","author":"Y Liao","year":"2014","unstructured":"Liao Y, Smyth GK, Shi W. FeatureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2014;30:923\u201330. https:\/\/doi.org\/10.1093\/bioinformatics\/btt656.","journal-title":"Bioinformatics"},{"key":"2775_CR24","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2010","unstructured":"Robinson MD, McCarthy DJ, Smyth GK. A bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26:139\u201340. https:\/\/doi.org\/10.1093\/bioinformatics\/btp616.","journal-title":"Bioinformatics"},{"key":"2775_CR25","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1093\/bioinformatics\/btz931","volume":"36","author":"SX Ge","year":"2020","unstructured":"Ge SX, Jung D, Yao R. ShinyGO: a graphical gene-set enrichment tool for animals and plants. Bioinformatics. 2020;36:2628\u20139. https:\/\/doi.org\/10.1093\/bioinformatics\/btz931.","journal-title":"Bioinformatics"},{"key":"2775_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s12859-015-0611-3","volume":"16","author":"H Heberle","year":"2015","unstructured":"Heberle H, Meirelles GV, da Silva FR, Telles GP, Minghim R. InteractiVenn: a web-based tool for the analysis of sets through Venn diagrams. BMC Bioinformatics. 2015;16:169. https:\/\/doi.org\/10.1186\/s12859-015-0611-3.","journal-title":"BMC Bioinformatics"},{"key":"2775_CR27","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41596-018-0082-x","volume":"14","author":"CS Hughes","year":"2019","unstructured":"Hughes CS, Moggridge S, M\u00fcller T, Sorensen PH, Morin GB, Krijgsveld J. Single-pot, solid-phase-enhanced sample preparation for proteomics experiments. Nat Protoc. 2019;14:68\u201385. https:\/\/doi.org\/10.1038\/s41596-018-0082-x.","journal-title":"Nat Protoc"},{"key":"2775_CR28","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41592-019-0638-x","volume":"17","author":"V Demichev","year":"2020","unstructured":"Demichev V, Messner CB, Vernardis SI, Lilley KS, Ralser M. DIA-NN: neural networks and interference correction enable deep proteome coverage in high throughput. Nat Methods. 2020;17:41\u20134. https:\/\/doi.org\/10.1038\/s41592-019-0638-x.","journal-title":"Nat Methods"},{"key":"2775_CR29","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/nmeth.3901","volume":"13","author":"S Tyanova","year":"2016","unstructured":"Tyanova S, Temu T, Sinitcyn P, Carlson A, Hein MY, Geiger T, et al. The Perseus computational platform for comprehensive analysis of (prote)omics data. Nat Methods. 2016;13:731\u201340. https:\/\/doi.org\/10.1038\/nmeth.3901.","journal-title":"Nat Methods"},{"key":"2775_CR30","doi-asserted-by":"publisher","first-page":"6441","DOI":"10.1093\/nar\/gkae165","volume":"52","author":"A Matsuda","year":"2024","unstructured":"Matsuda A, Plewka J, Rawski M, Mour\u00e3o A, Zajko W, Siebenmorgen T, et al. Despite the odds: formation of the SARS-CoV-2 methylation complex. Nucleic Acids Res. 2024;52:6441\u201358. https:\/\/doi.org\/10.1093\/nar\/gkae165.","journal-title":"Nucleic Acids Res"},{"key":"2775_CR31","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.semcdb.2013.01.003","volume":"24","author":"AW Duncan","year":"2013","unstructured":"Duncan AW. Aneuploidy, polyploidy and ploidy reversal in the liver. Semin Cell Dev Biol. 2013;24:347\u201356. https:\/\/doi.org\/10.1016\/j.semcdb.2013.01.003.","journal-title":"Semin Cell Dev Biol"},{"key":"2775_CR32","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1182\/blood-2010-08-300301","volume":"117","author":"T Riedel","year":"2011","unstructured":"Riedel T, Suttnar J, Brynda E, Houska M, Medved L, Dyr JE. Fibrinopeptides A and B release in the process of surface fibrin formation. Blood. 2011;117:1700\u20136. https:\/\/doi.org\/10.1182\/blood-2010-08-300301.","journal-title":"Blood"},{"key":"2775_CR33","doi-asserted-by":"publisher","unstructured":"van der Vorst EPC. High-Density Lipoproteins and Apolipoprotein A1. 2020. p. 399\u2013420. https:\/\/doi.org\/10.1007\/978-3-030-41769-7_16","DOI":"10.1007\/978-3-030-41769-7_16"},{"key":"2775_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0041966","volume":"7","author":"S Talens","year":"2012","unstructured":"Talens S, Leebeek FWG, Demmers JAA, Rijken DC. Identification of fibrin clot-bound plasma proteins. PLoS ONE. 2012;7:e41966. https:\/\/doi.org\/10.1371\/journal.pone.0041966.","journal-title":"PLoS ONE"},{"key":"2775_CR35","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2503044122","volume":"122","author":"J Cisowski","year":"2025","unstructured":"Cisowski J, El Zowalaty AE, Sayin SI, Czarnota P, Gromowski T, Eklund EA, et al. BRAF inhibition increases TGF\u03b22 production and stimulates metastasis in mice with endogenous BRAFV600E-induced hepatocellular carcinoma. Proc Natl Acad Sci U S A. 2025;122:e2503044122. https:\/\/doi.org\/10.1073\/pnas.2503044122.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2775_CR36","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1111\/cas.14130","volume":"110","author":"H Tanaka","year":"2019","unstructured":"Tanaka H, Horioka K, Yamamoto M, Asari M, Okuda K, Yamazaki K, et al. Overproduction of thrombopoietin by BRAFV600E \u2010mutated mouse hepatocytes and contribution of thrombopoietin to hepatocarcinogenesis. Cancer Sci. 2019;110:2748\u201359. https:\/\/doi.org\/10.1111\/cas.14130.","journal-title":"Cancer Sci"},{"key":"2775_CR37","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1002\/mc.22510","volume":"56","author":"M Yamamoto","year":"2017","unstructured":"Yamamoto M, Tanaka H, Xin B, Nishikawa Y, Yamazaki K, Shimizu K, et al. Role of the Braf V637E mutation in hepatocarcinogenesis induced by treatment with diethylnitrosamine in neonatal B6C3F1 mice. Mol Carcinog. 2017;56:478\u201388. https:\/\/doi.org\/10.1002\/mc.22510.","journal-title":"Mol Carcinog"},{"key":"2775_CR38","doi-asserted-by":"publisher","first-page":"4681","DOI":"10.1172\/JCI65764","volume":"123","author":"H Court","year":"2013","unstructured":"Court H, Amoyel M, Hackman M, Lee KE, Xu R, Miller G, et al. Isoprenylcysteine carboxylmethyltransferase deficiency exacerbates KRAS-driven pancreatic neoplasia via Notch suppression. J Clin Invest. 2013;123:4681\u201394. https:\/\/doi.org\/10.1172\/JCI65764.","journal-title":"J Clin Invest"},{"key":"2775_CR39","doi-asserted-by":"publisher","DOI":"10.1093\/jscr\/rjaf047","author":"TC Tsai","year":"2025","unstructured":"Tsai TC, Su CM. A case of hepatic sarcomatoid cholangiocarcinoma with diaphragmatic and right lower lobe lung invasion. J Surg Case Rep. 2025. https:\/\/doi.org\/10.1093\/jscr\/rjaf047.","journal-title":"J Surg Case Rep"},{"key":"2775_CR40","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.39520","author":"EA Zaher","year":"2023","unstructured":"Zaher EA, Patel P, Gotimukul A, Sqour H. Sarcomatoid Intrahepatic Cholangiocarcinoma: A Rare and Aggressive Primary Liver Cancer. Cureus. 2023. https:\/\/doi.org\/10.7759\/cureus.39520.","journal-title":"Cureus"},{"key":"2775_CR41","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1126\/science.1238880","volume":"340","author":"MX Ibrahim","year":"2013","unstructured":"Ibrahim MX, Sayin VI, Akula MK, Liu M, Fong LG, Young SG, et al. Targeting isoprenylcysteine methylation ameliorates disease in a mouse model of progeria. Science. 2013;340:1330\u20133. https:\/\/doi.org\/10.1126\/science.1238880.","journal-title":"Science"},{"key":"2775_CR42","doi-asserted-by":"publisher","first-page":"5841","DOI":"10.1074\/jbc.C000831200","volume":"276","author":"MO Bergo","year":"2001","unstructured":"Bergo MO, Leung GK, Ambroziak P, Otto JC, Casey PJ, Gomes AQ, et al. Isoprenylcysteine carboxyl methyltransferase deficiency in mice. J Biol Chem. 2001;276:5841\u20135. https:\/\/doi.org\/10.1074\/jbc.C000831200.","journal-title":"J Biol Chem"},{"key":"2775_CR43","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1172\/JCI78585","volume":"125","author":"S J\u00f6rs","year":"2015","unstructured":"J\u00f6rs S, Jeliazkova P, Ringelhan M, Thalhammer J, D\u00fcrl S, Ferrer J, et al. Lineage fate of ductular reactions in liver injury and carcinogenesis. J Clin Invest. 2015;125:2445\u201357. https:\/\/doi.org\/10.1172\/JCI78585.","journal-title":"J Clin Invest"},{"key":"2775_CR44","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.jhep.2021.11.010","volume":"76","author":"Y Liu","year":"2022","unstructured":"Liu Y, Zhuo S, Zhou Y, Ma L, Sun Z, Wu X, et al. Yap-Sox9 signaling determines hepatocyte plasticity and lineage-specific hepatocarcinogenesis. J Hepatol. 2022;76:652\u201364. https:\/\/doi.org\/10.1016\/j.jhep.2021.11.010.","journal-title":"J Hepatol"},{"key":"2775_CR45","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s00204-016-1694-y","volume":"91","author":"JA Heslop","year":"2017","unstructured":"Heslop JA, Rowe C, Walsh J, Sison-Young R, Jenkins R, Kamalian L, et al. Mechanistic evaluation of primary human hepatocyte culture using global proteomic analysis reveals a selective dedifferentiation profile. Arch Toxicol. 2017;91:439\u201352. https:\/\/doi.org\/10.1007\/s00204-016-1694-y.","journal-title":"Arch Toxicol"},{"key":"2775_CR46","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/ejh.13688","volume":"107","author":"HS McMurry","year":"2021","unstructured":"McMurry HS, Jou J, Shatzel J. The hemostatic and thrombotic complications of liver disease. Eur J Haematol. 2021;107:383\u201392. https:\/\/doi.org\/10.1111\/ejh.13688.","journal-title":"Eur J Haematol"},{"key":"2775_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11081097","volume":"11","author":"K Georgila","year":"2019","unstructured":"Georgila K, Vyrla D, Drakos E. Apolipoprotein A-I (ApoA-I), immunity, inflammation and cancer. Cancers (Basel). 2019;11:1097. https:\/\/doi.org\/10.3390\/cancers11081097.","journal-title":"Cancers (Basel)"},{"key":"2775_CR48","doi-asserted-by":"publisher","first-page":"70654","DOI":"10.18632\/oncotarget.12203","volume":"7","author":"X-L Ma","year":"2016","unstructured":"Ma X-L, Gao X-H, Gong Z-J, Wu J, Tian L, Zhang C-Y, et al. Apolipoprotein A1: a novel serum biomarker for predicting the prognosis of hepatocellular carcinoma after curative resection. Oncotarget. 2016;7:70654\u201368. https:\/\/doi.org\/10.18632\/oncotarget.12203.","journal-title":"Oncotarget"},{"key":"2775_CR49","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1002\/pmic.200500257","volume":"6","author":"J Ai","year":"2006","unstructured":"Ai J, Tan Y, Ying W, Hong Y, Liu S, Wu M, et al. Proteome analysis of hepatocellular carcinoma by laser capture microdissection. Proteomics. 2006;6:538\u201346. https:\/\/doi.org\/10.1002\/pmic.200500257.","journal-title":"Proteomics"},{"key":"2775_CR50","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41586-019-0987-8","volume":"567","author":"Y Jiang","year":"2019","unstructured":"Jiang Y, Sun A, Zhao Y, Ying W, Sun H, Yang X, et al. Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma. Nature. 2019;567:257\u201361. https:\/\/doi.org\/10.1038\/s41586-019-0987-8.","journal-title":"Nature"},{"key":"2775_CR51","doi-asserted-by":"publisher","first-page":"3640","DOI":"10.1074\/mcp.M113.031252","volume":"12","author":"MG Mustafa","year":"2013","unstructured":"Mustafa MG, Petersen JR, Ju H, Cicalese L, Snyder N, Haidacher SJ, et al. Biomarker discovery for early detection of hepatocellular carcinoma in hepatitis C\u2013infected patients. Mol Cell Proteomics. 2013;12:3640\u201352. https:\/\/doi.org\/10.1074\/mcp.M113.031252.","journal-title":"Mol Cell Proteomics"},{"key":"2775_CR52","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1002\/pmic.200300399","volume":"3","author":"LF Steel","year":"2003","unstructured":"Steel LF, Shumpert D, Trotter M, Seeholzer SH, Evans AA, London WT, et al. A strategy for the comparative analysis of serum proteomes for the discovery of biomarkers for hepatocellular carcinoma. Proteomics. 2003;3:601\u20139. https:\/\/doi.org\/10.1002\/pmic.200300399.","journal-title":"Proteomics"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-026-02775-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-026-02775-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-026-02775-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:47:22Z","timestamp":1781639242000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12964-026-02775-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,11]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2775"],"URL":"https:\/\/doi.org\/10.1186\/s12964-026-02775-6","relation":{},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,11]]},"assertion":[{"value":"1 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal procedures were conducted in accordance with the Guide for the Care and Use of Laboratory Animals (Directive 2010\/63\/EU of the European Parliament) and carried out under a license from the 2nd Local Institutional Animal Care and Use Committee in Krak\u00f3w (approval no. 99\/2023).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"232"}}